W. Keith Tan

8/8 Massive thanks to PhD funder @CR_UK , and all co-authors & collaborators @petersasieni @massi_dipietro @anjan_dhar6 @DrVinaySehgal1 @DrDanielleMorr1 @barrettsonline

7/8 Possible options: ✅1⃣ Sponge integration into surveillance + centralisation of high risk cases- replaces 50% OGD with sponge 2⃣ Centralisation of surveillance altogether - unrealistic 3⃣ Avoid surveillance in low risk given low cancer risk- Radical but sensible (cut 50% OGD)

1/8 🎉Thrilled to share our landmark study now published in @TheLancet on a capsule sponge surveillance strategy for Barrett's oesophagus thelancet.com/journals/lance… presented at the @BritSocGastro, Glasgow @Cambridge_Uni @EarlyCancerCam @addenbrookes @CR_UK @RFitzgerald_lab

Such an honour to speak at the Distinguished Plenary Session at DDW San Diego 2025 and to meet the legends in the field of Barrett's oesophagus and oesophageal cancer

Honored to share the stage with @RadioDoctorKatz, @HimanshuNagarMD, and @mbrothberg discussing novel perspectives on focal therapy for prostate cancer at the @FocalSociety meeting. @NYUUrology, @NYULISOM_U, @DukeUrology, @Endo_Society 🦾. Shoutout to @tanejauro for the awesome📸!

An honour and privilege to be awarded the UK Barrett's Oesophagus Registry (UKBOR) prize by @BritSocGastro

Well done, Keith! @DrWKTan @BritSocGastro UKBOR prize

Ever thought you are doing too many negative cystoscopies for patients with hematuria? Our report in @EurUrolOncol utilizes a hematuria nomogram and ultrasound to triage patients for cystoscopy= 25% of hematuria patients avoiding cystoscopy #oncsurgery tinyurl.com/mu2zp3f7

.@nyulangone is now a SpaceOAR™ Center of Excellence! Thanks, @DrTanWP for your dedication to #prostatecancer patients & helping them protect their quality of life while undergoing RT. A little space can make a BIG difference!

Congratulations to members of the @RFitzgerald_lab who had great success at the @DDWMeeting recently. @DrWKTan gave three oral presentations with one chosen as distinguished abstract for the plenary session. Professor Fitzgerald gave the Morton I. Grossman Distinguished Lecture.

An honour to speak at the Distinguished Plenary Session at Digestive Disease Week Washington DC and to meet some of the legends of Barretts esophagus and esophageal cancer #DDW2024 @EarlyCancerCam @DDWMeeting

Our latest study in Gastro suggests a Targeted Screening Strategy for Barrett's Esophagus to Enrich the Screening Population. I will present our findings at the Plenary session of DDW in Washington D.C on 20th May 4pm. See you there! #AGA_Gastro #DDW2024 gastrojournal.org/article/S0016-…

@WFostier MRCP serves no purpose other than being mandatory for IMT. It is a 'buzzword' exam ie cobblestone appearance of colon= Crohn's. USMLE test understanding of concepts. I learned a lot from USMLE but not from MRCP. Coming from someone who have sat P1/P2 CK/CS/P3 and MRCP 1/2/paces.

Recently sat (and passed) the Membership of the Royal Colleges of Physicians (MRCP) part one examination. I have taken a host of exams pre- and post- medical school, including US exams (SAT, USMLE Step 1/Step 2). MRCP P1 struck me as an anomaly in terms of timing and purpose.